More news
- PPG honoured with American Chemistry Council Sustainability Leadership Award
- Manufacturing businesses set to benefit as UK concludes tax agreement with Peru and ratifi...
- Asian Paints releases financial results
- BASF now offering first biomass-balanced products for its ammonia and urea portfolio
- Songwon announces Q1/2024 financial results
Chief Executive Officer (CEO) of Ambu A/S, Britt Meelby Jensen, has been nominated to replace Susanna Schneeberger as board member of Hempel A/S.
At the Annual General Meeting of Hempel A/S on 2 May 2024, Britt Meelby Jensen will be put forward for election as member of the Board of Directors of Hempel A/S.
As CEO of Ambu A/S, Britt Meelby Jensen comes with extensive experience from the life science industry, where she has served in various leadership roles in global companies for more than two decades. From 2019, Britt Meelby Jensen was CEO of Swedish Atos Medical until she led the sale of the company to Coloplast in early 2022. From 2015 to 2019, Britt Meelby Jensen was CEO of Zealand Pharma. Prior to this, Britt Meelby Jensen served as CEO of Dako and held several leadership positions in Novo Nordisk.
Britt Meelby Jensen has been a board member of the Hempel Foundation and Hempel Invest A/S since 2018. Once elected for the Hempel A/S Board of Directors, Britt Meelby Jensen will step down as board member of the Hempel Foundation and Hempel Invest A/S. She holds an MSc in International Marketing and Management from Copenhagen Business School and an MBA from Solvay Business School in Brussels. Britt Meelby Jensen is also an incumbent board member of Novo Holdings.
“I am thrilled that Britt Meelby Jensen has accepted to be nominated for the Hempel A/S Board of Directors. With more than 20 years’ experience within healthcare and general management, alongside her contribution to the Hempel Foundation board and the Hempel Invest A/S board, we are convinced that Britt Meelby Jensen is the right profile to join the Hempel A/S Board of Directors,” comments Richard Sand, Chairman of the Board of Directors of Hempel A/S and continues, “Britt Meelby Jensen brings to Hempel extensive international experience and expertise within leadership of global corporations and she will play an important role in Hempel’s ambitious growth journey. The Hempel Foundation and Hempel Invest A/S have already greatly benefited from her profound business insight and strong leadership and we now look forward to bringing this expertise to the Hempel A/S board.”
Britt Meelby Jensen replaces Susanna Schneeberger on the Hempel A/S board. Susanna Schneeberger has served on the board since 2018 and has made outstanding contributions in developing Hempel A/S into a growing global enterprise.
Susanna Schneeberger has decided not to run for re-election to make better room for her other board assignments.
“On behalf of the Board of Directors, I would like to take this opportunity to thank Susanna Schneeberger for her very valuable contribution to the Hempel Group over the past six years,” says Richard Sand.
The entire Board of Directors of Hempel A/S consists of 9 members.
